Related references
Note: Only part of the references are listed.Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials
Tobias Derfuss et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program
Vincent van Pesch et al.
ACTA NEUROLOGICA BELGICA (2014)
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2013)
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study
Amit Bar-Or et al.
JOURNAL OF NEUROLOGY (2013)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Virginia Devonshire et al.
LANCET NEUROLOGY (2012)
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
Aaron E. Miller et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Gavin Giovannoni et al.
LANCET NEUROLOGY (2011)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2009)
Disability progression in multiple sclerosis is slower than previously reported
H Tremlett et al.
NEUROLOGY (2006)
Share Paper
